WNK2 and neoplasm: Although the results of the clinical trial have not been published, its predecessor compounds (ARS-853 and ARS-1620) are able to induce tumor regression in PDX models and block downstream signaling to mitogen-activated protein kinase (MAPK) in KRASG12C-mutant tumor cell lines [65, 74].